Produkty 73036-31-4

CAS 73036-31-4 występuje w naszej ofercie pod nazwami: Epigomisin O, Epigomisin O, Epigomisin O, ≥98%, ≥98%, Epigomisin O, 99.60%. Oferty producentów: GLPBio, Biosynth, Chemat, MedChemExpress. Dostępne opakowania: 5mg, 1mg, 10mg, 1 mg.

Epigomisin O
GLPBio
  • opakowanie: 5mg, 1mg
  • Warianty: 2
od 1299,11
Zobacz produkt
Epigomisin O
Biosynth
  • opakowanie: 5mg, 1mg, 10mg
  • Warianty: 3
Zobacz produkt
Epigomisin O, ≥98%, ≥98%
Chemat
  • opakowanie: 5mg
  • Warianty: 1
od 1691,60
Zobacz produkt
Epigomisin O, 99.60%
MedChemExpress
  • opakowanie: 1 mg
  • Warianty: 1
od 1127,75
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(8S,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-ol (CAS 73036-31-4) to związek chemiczny o wzorze sumarycznym C23H28O7 i masie molowej 416.5 g/mol. Nazwa systematyczna IUPAC: (8S,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-ol. InChIKey: GWDFJIBHVSYXQL-ZKTNFTSUSA-N.

Dane identyfikacyjne
Wzór sumarycznyC23H28O7
Masa molowa416.5 g/mol
Nazwa IUPAC(8S,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-ol
InChIKeyGWDFJIBHVSYXQL-ZKTNFTSUSA-N
SMILESC[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4[C@H]([C@H]1C)O)OC)OC)OC)OC)OCO3

Dane obliczone przez PubChem (NCBI)

Synonimy: Epigomisin O, EpigomisinO, orb1684628
Powiązane formy tego związku
(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-ol C23H28O7
Izomery (ten sam wzór sumaryczny)
[2-[(8S,9S,10R,13S,14S,16R,17S)-16,17-dihydroxy-10,13-dimethyl-3,11-dioxo-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate C23H28O7
[2-oxo-2-[(8R,9S,10R,11S,13S,16R,17S)-11,16,17-trihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,16-hexahydro-6H-cyclopenta[a]phenanthren-17-yl]ethyl] acetate C23H28O7
(2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-[3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]oxane-3,4,5-triol C23H28O7
[2-[(1S,2S,10S,11S,13R,14S,15S,17S)-13,14-dihydroxy-2,15-dimethyl-5-oxo-18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadeca-3,6-dien-14-yl]-2-oxoethyl] acetate C23H28O7
(2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol C23H28O7
3-(3,4-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan C23H28O7
(3S,3aR,6R,6aR)-3-(3,4-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan C23H28O7
(9R,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-9-ol C23H28O7
[(3R,5R)-5-acetyloxy-7-(3,4-dihydroxyphenyl)-1-(4-hydroxyphenyl)heptan-3-yl] acetate C23H28O7
(2S,3S,4S,5R,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol C23H28O7
(3R,3aR,6S,6aR)-3-(3,5-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan C23H28O7